At the Intersection of
Plant Medicine
& Technology
Rose Hill Life Sciences is pioneering the next generation of neurological therapeutics, combining ancient plant wisdom with cutting-edge clinical science to unlock new pathways for healing.
Healing through Nature & Science
Our mission is to revolutionize healthcare by bridging the gap between ancient plant wisdom and modern pharmaceutical science. We are dedicated to developing safe, effective, and accessible psychedelic therapeutics for those suffering from treatment-resistant conditions.
"We believe the future of psychiatry lies in the responsible integration of plant-derived compounds into mainstream medicine."
Patient-Centricity
Every decision we make is guided by the potential to improve patient outcomes and quality of life.
Scientific Integrity
We adhere to the highest standards of rigorous scientific validation and regulatory compliance.
Innovation
We push the boundaries of what's possible in plant medicine through advanced biotechnology.
Accessibility
We are committed to developing treatments that are scalable, affordable, and accessible to all.
First-Mover Advantage in
Stroke Recovery
Rose Hill is a vertically integrated psychedelic therapeutics company developing psilocybin-based treatments for neurological and psychiatric conditions.
Our flagship program—in exclusive partnership with Johns Hopkins University—represents the world's first clinical trial investigating psilocybin for post-stroke motor recovery, targeting a $46 billion market with zero psychedelic competition.
Unlocking Potential in
Autism & Neurodevelopment
Beyond stroke recovery, Rose Hill is applying its "critical period" reopening thesis to neurodevelopmental disorders, addressing the root causes of social and behavioral challenges.
Current treatments only manage symptoms like irritability. We are targeting core social and communication deficits in a rapidly growing market projected to reach $15.3 billion by 2032.
Next-Generation
Tryptamine Therapeutics
Rose Hill is establishing a DEA Schedule I compliant research environment to develop novel delivery systems and differentiated formulations.
This program focuses on creating proprietary oral and transdermal delivery technologies, generating early-stage IP assets, and advancing synthetic tryptamines toward preclinical readiness.
Fully compliant infrastructure enabling lawful import, extraction, and synthesis of natural and synthetic tryptamines.
Psychedelic Therapeutic
Interventions™
We are developing a scalable, manualized therapeutic framework for treating PTSD, with a primary focus on veterans. This protocol leverages Colorado's legal landscape to offer immediate, structured care.
Our CBT-inspired model integrates pre-dose preparation, a supervised dosing weekend, and 6+ months of integration support, creating a replicable standard for psychedelic therapy.
Optimizing Psilocybin for Therapeutic Use
Our proprietary extraction and formulation technologies maximize the bioavailability and stability of natural psilocybin, creating a consistent pharmaceutical-grade product from biological sources.
Enhanced Bioavailability
Novel lipid-based delivery systems increase absorption and reduce onset time.
Precision Dosing
Standardized formulations ensure consistent therapeutic outcomes for every patient.
Natural Synergy
Preserving the entourage effect of minor alkaloids while eliminating impurities.
Psilocybin
C₁₂H₁₇N₂O₄P
Mol. Mass
284.25 g/mol
Diversified Pipeline
Four clinical programs across neurological and psychiatric conditions, reducing single-program risk while targeting massive unmet needs.
Investment
Thesis
Rose Hill represents a unique opportunity to invest in a de-risked, high-growth biotech asset with a clear path to liquidity.
First-Mover Advantage
Only company pursuing psilocybin for stroke recovery—zero psychedelic competitors in $46B market.
Johns Hopkins Partnership
Exclusive worldwide license to groundbreaking patent with world-class researchers leading trials.
Vertical Integration
In-house cultivation provides supply chain control, margin advantage, and quality assurance.
Diversified Pipeline
Four clinical programs across stroke, autism, depression, and PTSD reduces single-program risk.
Proven Exit Market
$1.6B+ in psychedelic M&A closed in 2025 validates acquisition pathway at premium valuations.
Experienced Team
Leadership with drug development, regulatory strategy, and commercial expertise.
2025 M&A Momentum
Over $1.6 Billion in psychedelic deals closed in 2025, validating the exit market and premium valuations for clinical-stage assets.
AbbVie Acquires Gilgamesh Pharmaceuticals
First Big Pharma acquisition of a psychedelic asset, validating that Phase 2 data can command billion-dollar valuations.
Atai Life Sciences + Beckley Psytech Merger
Major consolidation event creating a market leader, demonstrating the premium placed on regulatory designations.
The Right Team
Combining deep expertise in drug development, regulatory strategy, and commercial execution.
Charles Lazarus
Over a decade of expertise in psilocybin genetic development, cultivation, extraction, and logistics. Developed proprietary psilocybin genetics for the Jamaican market and major R&D clients. Previously owned Island Fresh Ltd., achieving highest export volumes from Jamaica to UK.
Burton J. Tabaac, MD, FAHA
Associate Professor and Section Chief of Neurology at University of Nevada, Reno. Medical Director of Stroke at Carson Tahoe Health. Completed fellowship at Johns Hopkins. Research focuses on psychedelics for brain injuries and stroke rehabilitation.
Rotem Petranker, PhD
Leading psychedelics researcher specializing in microdosing, therapy, and research ethics. Founder of Canadian Centre for Psychedelic Science. Currently conducting pivotal clinical trial on microdosing psilocybin for Major Depressive Disorder.
Kevin Bourke
Over 20 years of marketing expertise with leading Jamaican brands like Appleton Estate Rum and Usain Bolt's Tracks & Records. Successfully transitioned into the psilocybin industry, ensuring brand integrity and customer satisfaction.
Jama Pitman
Seasoned biopharma executive with 20+ years experience. Guided companies through IPOs, M&A, and FDA approvals. At Deciphera Pharmaceuticals, helped scale from small biotech to $2.4B acquisition. Led development of multiple FDA-approved therapies.
Domenic Suppa
Former COO of Evolabs (acquired by Harvest Health). Acting COO of manufacturing for Supreme Cannabis. Collaborated with prominent national cannabis brands. Expert in process efficiency and minimizing waste in early-stage growth enterprises.
Adam Goodman
Seasoned entrepreneur in real estate development managing over 6 million sq ft across 23 states. Diversified experience in alternative investments including healthcare, professional sports franchises, and financial services.
Delia A. Deschaine
Recognized Washington DC Rising Star attorney specializing in FDA and DEA regulations. Advises on drug development, approval, pharmacovigilance, and corporate legal transactions for pharmaceutical and biotechnology clients.
Our Partners
Working with world-leading institutions to pioneer psychedelic science.
Johns Hopkins University
Gül Dölen, MD, PhD
Neuroscientist known for studying social behavior, psychedelic drugs and critical periods. Discovered that oxytocin and serotonin interact in the nucleus accumbens to produce social rewards. Her research suggests a common genetic basis of social behavior across the animal kingdom.
Steven Zeiler, MD, PhD
Focuses on diagnosis and management of cerebrovascular disease (stroke), including acute stroke therapy, secondary prevention, and recovery. Completed residency in Neurology and fellowship in Vascular Neurology at Johns Hopkins.
University of Guelph
Melissa L. Perreault, PhD
Translational research focus on sex differences in cellular mechanisms underlying neurodevelopmental and neuropsychiatric disorders. Discovers sex-specific neurophysiological patterns as biomarkers. Focuses on ethical research methodologies in Indigenous communities.
Andrew Maxwell Phineas Jones
Professor in the Department of Plant Agriculture supporting the mission of the Gosling Research Institute for Plant Preservation (GRIPP). Acting Graduate Coordinator for the Department of Plant Agriculture.
Global Research Footprint
Industry News
Psychedelic Drugs Market Poised for $1.94 Billion Growth
New market analysis projects substantial growth in the sector through 2029, driven by increasing clinical validation and regulatory progress.
AbbVie's $1.2 Billion Deal Signals Pharma's Embrace of Psychedelics
Major pharmaceutical acquisition marks a turning point for the industry, with Compass, J&J, and Otsuka showing increased activity in the space.
Synthetic Psilocybin Nears FDA Review
A form of psilocybin is now on the brink of mainstream medical acceptance as it approaches final regulatory review stages.
New Psilocybin Study Targets Treatment-Resistant Depression
Latest clinical trials show promising results for patients with anhedonia and major depressive disorder who haven't responded to traditional treatments.
Join the Revolution
Rose Hill Life Sciences is positioned to lead the next generation of psychedelic therapeutics. Contact us to learn more about the investment opportunity or request access to our full data room.